Zoetis Inc. $ZTS Shares Sold by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC cut its stake in Zoetis by 49.1% in Q3, selling 431,642 shares and retaining 447,340 shares worth about $65.46 million.
• Zoetis beat quarterly expectations with EPS of $1.48 versus a $1.40 consensus and revenue of $2.39 billion (+3% YoY), and set FY 2026 guidance of 7.00–7.10 EPS.
• The company declared a quarterly dividend of $0.53 (annualized $2.12, yield 1.7%, ex-dividend April 20) and roughly 92.8% of its stock is held by institutional investors.

Natixis Advisors LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 49.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 447,340 shares of the company's stock after selling 431,642 shares during the quarter. Natixis Advisors LLC owned 0.10% of Zoetis worth $65,455,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. CIBC Asset Management Inc grew its holdings in shares of Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company's stock worth $36,745,000 after acquiring an additional 10,434 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company's stock valued at $43,235,000 after purchasing an additional 18,040 shares during the period. Ninety One UK Ltd increased its stake in Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company's stock worth $163,751,000 after purchasing an additional 183,686 shares in the last quarter. Quilter Plc raised its holdings in Zoetis by 10.2% during the 3rd quarter. Quilter Plc now owns 438,959 shares of the company's stock worth $64,228,000 after buying an additional 40,615 shares during the period. Finally, Swedbank AB lifted its stake in Zoetis by 60.4% during the third quarter. Swedbank AB now owns 2,436,888 shares of the company's stock valued at $356,565,000 after buying an additional 917,598 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 0.6%

NYSE ZTS opened at $121.54 on Monday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The firm's fifty day simple moving average is $126.06 and its 200-day simple moving average is $132.88. The company has a market capitalization of $51.31 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period in the previous year, the company earned $1.40 EPS. The firm's revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis's dividend payout ratio is 35.22%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ZTS shares. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. Bank of America lifted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research report on Friday, February 13th. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They issued a "sector weight" rating for the company. Finally, Barclays began coverage on Zoetis in a report on Monday, December 8th. They set an "equal weight" rating and a $136.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.